Sectors

The Tencent and Warner Music-backed game development platform looks set to maintain its $29.5bn valuation in its direct listing today.

Koch Disruptive Technologies has provided $110m for the drug discovery technology startup's series B round following a $190m first close in January.

Motorola Solutions is among the participants supplying $300m in PIPE financing as the contactless security system developer agrees to list through a reverse takeover.

Deutsche Telekom-backed DTCP was among a group of investors that acquired a $270m stake in the cybersecurity management platform developer in a secondary transaction.

The computational pathology technology provider has added $25m to a round co-led by Johnson & Johnson Innovation – JJDC.

Novo will exit the musculoskeletal disease drug developer, should the latter complete an initial public offering on the Nasdaq Global Market.

The Ideo, Bonnier, JR East, and Demand Analytics-backed urban farm owner has pulled in new equity and debt financing from existing investors.

SR One is line for an exit from the small-molecule therapy developer, which has raised $170m in venture funding in the past year.

The immuno-oncology company, based on University of Turin research, has completed a $21m series B round led by Claris Ventures.

Max Planck spinout Quench Bio will wind down after its target proved undruggable and will return capital to investors, which include AbbVie Ventures.

Astellas Venture Management is among the new investors in the cancer immunotherapy developer, which was spun off by PhoreMost four years ago.